## STE: STERIS plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.6% below STRENGTH zone (4.0-10.0%); PEG 1.75 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (48% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($247.30)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Valley National Advisers Inc. Invests $2.04 Million in STERIS plc $STE**
- Source: MarketBeat | 20251228T130139 | Bullish | Relevance: 100%
- Valley National Advisers Inc. recently acquired a new stake of 8,265 shares in STERIS plc (NYSE:STE) during the third quarter, valued at approximately $2.04 million. This investment comes amidst significant institutional ownership of 94.69% and recent insider selling totaling $6.62 million. STERIS, a medical equipment provider, reported strong Q3 results, beating EPS and revenue estimates, and has a "Moderate Buy" consensus rating from analysts with an average price target of $273.50.

**2. Harbor Capital Advisors Inc. Has $633,000 Stock Position in STERIS plc $STE**
- Source: MarketBeat | 20251228T111054 | Somewhat-Bullish | Relevance: 100%
- Harbor Capital Advisors Inc. significantly reduced its stake in STERIS plc by 71.1% in Q3, now holding 2,559 shares valued at approximately $633,000. Despite recent insider selling totaling $6.62 million, STERIS recently surpassed quarterly EPS estimates and provided optimistic FY2026 guidance. The company, which pays a quarterly dividend of $0.63, has a market cap of $25.06 billion, a consensus analyst target of $273.50, and institutional ownership of 94.69%.

**3. STERIS's SWOT analysis: infection prevention leader's stock poised for growth**
- Source: MSN | 20251228T110906 | Bullish | Relevance: 100%
- This article analyzes STERIS plc (STE) using a SWOT framework, highlighting its strengths in the infection prevention market, opportunities for growth, potential weaknesses, and external threats. It suggests that STERIS's strong market position and strategic acquisitions make its stock an attractive investment.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 11 ($0.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.4% (+0.4%)
- Blackrock Inc.: 8.9% (+1.3%)
- Massachusetts Financ: 4.9% (-7.7%)
- State Street Corpora: 4.4% (+4.0%)
- Morgan Stanley: 4.3% (+8.3%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.75 elevated, pricing in significant growth expectations. Forward P/E 23.0x stretched relative to 9% growth. Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.48). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $25.2B |
| Beta | 1.01 |
| 52W Range | $200.98 - $268.60 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.75 |
| Forward P/E | 23.0 |
| Current P/E | 25.1 |
| YoY Growth | 9.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -1.9% to -0.6% (+1.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.5pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.5%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.07x) but short-term weakness (below SMA20). RSI neutral at 51. Volume at 48% of 20MA suggests lack of conviction. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.55% (CS: 37) | Neutral |
| RSI_14 | 50.9 | Neutral |
| MACD Histogram | -0.25 | Bearish |
| vs SMA20 | 0.998x | Below |
| vs SMA50 | 1.009x | Above |
| vs SMA200 | 1.067x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $256.10
- **Stop Loss:** $247.30 (3.4% risk)
- **Target:** $264.90 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 156
- **Position Value:** $39,951.60
- **Portfolio %:** 39.95%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

**Next:** 2026-02-04 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.47 | +5.1% |
| 2025Q2 | $2.26 | $2.34 | +3.4% |
| 2025Q1 | $2.60 | $2.74 | +5.4% |
| 2024Q4 | $2.32 | $2.32 | -0.1% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*